Evaluation of the ovarian cancer antigen, CA-125, as a tumor marker

M. Onetto; M. Bruzzone; P. F. Conte; M. Ruvolo; A. Conio; S. Chiara; A. Falcone; G. Bentivoglio; G. E. Serra; M. Paganuzzi

doi:10.1159/000226697

Evaluation of the ovarian cancer antigen, CA-125, as a tumor marker

M. Onetto, M. Bruzzone, P. F. Conte, M. Ruvolo, A. Conio, S. Chiara, A. Falcone, G. Bentivoglio, G. E. Serra, M. Paganuzzi

Research output: Contribution to journal › Article › peer-review

Abstract

The presence of the Ca-125 antigen was tested in the serum of 46 patients with ovarian cancer in order to determine the prognostic value of preoperative levels and its usefulness for monitoring the clinical response in longitudinal studies, survival (S) and progression-free survival (PFS) were also evaluated. In our series, the specificity of the assay in normal subjects and in patients with benign gynecological diseases is 99.3 and 73.2% respectively, and the sensitivity is 91.9%. Preoperative Ca-125 levels are not correlated with S and PFS, whereas an advantage in S and PFS is clearly shown for patients in whom the marker level decreases after treatment. Serial determinations of Ca-125 scrum levels provide a reliable test to assess response to therapy and to predict disease progression.

Original language	English
Pages (from-to)	117-122
Number of pages	6
Journal	Oncology
Volume	46
Issue number	2
DOIs	https://doi.org/10.1159/000226697
Publication status	Published - 1989

Keywords

CA-125
Ovarian cancer
Tumor markers

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1159/000226697

Cite this

@article{66c3e517fbef4f7fbb0c2b0a5bbc8ca5,

title = "Evaluation of the ovarian cancer antigen, CA-125, as a tumor marker",

abstract = "The presence of the Ca-125 antigen was tested in the serum of 46 patients with ovarian cancer in order to determine the prognostic value of preoperative levels and its usefulness for monitoring the clinical response in longitudinal studies, survival (S) and progression-free survival (PFS) were also evaluated. In our series, the specificity of the assay in normal subjects and in patients with benign gynecological diseases is 99.3 and 73.2% respectively, and the sensitivity is 91.9%. Preoperative Ca-125 levels are not correlated with S and PFS, whereas an advantage in S and PFS is clearly shown for patients in whom the marker level decreases after treatment. Serial determinations of Ca-125 scrum levels provide a reliable test to assess response to therapy and to predict disease progression.",

keywords = "CA-125, Ovarian cancer, Tumor markers",

author = "M. Onetto and M. Bruzzone and Conte, {P. F.} and M. Ruvolo and A. Conio and S. Chiara and A. Falcone and G. Bentivoglio and Serra, {G. E.} and M. Paganuzzi",

year = "1989",

doi = "10.1159/000226697",

language = "English",

volume = "46",

pages = "117--122",

journal = "Oncology",

issn = "0030-2414",

publisher = "UBM Medica Healthcare Publications",

number = "2",

}

TY - JOUR

T1 - Evaluation of the ovarian cancer antigen, CA-125, as a tumor marker

AU - Onetto, M.

AU - Bruzzone, M.

AU - Conte, P. F.

AU - Ruvolo, M.

AU - Conio, A.

AU - Chiara, S.

AU - Falcone, A.

AU - Bentivoglio, G.

AU - Serra, G. E.

AU - Paganuzzi, M.

PY - 1989

Y1 - 1989

N2 - The presence of the Ca-125 antigen was tested in the serum of 46 patients with ovarian cancer in order to determine the prognostic value of preoperative levels and its usefulness for monitoring the clinical response in longitudinal studies, survival (S) and progression-free survival (PFS) were also evaluated. In our series, the specificity of the assay in normal subjects and in patients with benign gynecological diseases is 99.3 and 73.2% respectively, and the sensitivity is 91.9%. Preoperative Ca-125 levels are not correlated with S and PFS, whereas an advantage in S and PFS is clearly shown for patients in whom the marker level decreases after treatment. Serial determinations of Ca-125 scrum levels provide a reliable test to assess response to therapy and to predict disease progression.

AB - The presence of the Ca-125 antigen was tested in the serum of 46 patients with ovarian cancer in order to determine the prognostic value of preoperative levels and its usefulness for monitoring the clinical response in longitudinal studies, survival (S) and progression-free survival (PFS) were also evaluated. In our series, the specificity of the assay in normal subjects and in patients with benign gynecological diseases is 99.3 and 73.2% respectively, and the sensitivity is 91.9%. Preoperative Ca-125 levels are not correlated with S and PFS, whereas an advantage in S and PFS is clearly shown for patients in whom the marker level decreases after treatment. Serial determinations of Ca-125 scrum levels provide a reliable test to assess response to therapy and to predict disease progression.

KW - CA-125

KW - Ovarian cancer

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0024502640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024502640&partnerID=8YFLogxK

U2 - 10.1159/000226697

DO - 10.1159/000226697

M3 - Article

C2 - 2710476

AN - SCOPUS:0024502640

SN - 0030-2414

VL - 46

SP - 117

EP - 122

JO - Oncology

JF - Oncology

IS - 2

ER -

Evaluation of the ovarian cancer antigen, CA-125, as a tumor marker

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this